By Dr. Robert Den MD and Dr. Vered Domankevich PhD
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is a novel intratumoral radiotherapeutic technology that not only seeks to destroy tumors locally but also may trigger powerful immune system activation. By implanting tiny Radium-224 sources directly into a tumor, clinicians use Alpha DaRT to deliver high-energy alpha radiation that causes cancer cell death and extensive DNA damage in tumor cells. [1,2] This localized destruction can be highly immunogenic – as tumor cells die, they release a flood of tumor antigens and “danger” signals (DAMPs) that alert the immune system. [3,4] When this occurs, the tumor can essentially become an in-situ vaccine, stimulating the body’s own defense to recognize and attack cancer cells throughout the body. [5,6] In fact, Alpha DaRT has demonstrated a strong immune stimulatory effect, suggesting it may be combined with immunotherapy for an enhanced systemic effect against metastases. [7,8]
How Alpha DaRT “Heats Up” the Immune Response
Research shows that Alpha DaRT may convert an immunologically “cold” tumor microenvironment into a “hot” one, rich with activated immune cells. [7] Key immune changes observed in pre-clinical experiments include:
- Increased T Cell Infiltration: Tumors show higher influx of CD3⁺ and CD8⁺ T cells (the “killer” T cells) after being treated with Alpha DaRT, indicating the immune system is homing in on the cancer. [7] In preclinical models, Alpha DaRT even induced long-term immune memory – treated mice resisted re-challenge with new tumor cells, demonstrating a vaccine-like effect. [5,8]
- Activation of Dendritic Cells: Alpha DaRT is associated with activation of dendritic cells (the immune system’s antigen-presenting sentinels). [7] This is critical, as dendritic cells process tumor antigens from the irradiated tumor and present them to T cells, kick-starting a broader anti-tumor immune response. [3,4]
- Reduction of Immunosuppressive Cells: Studies found fewer Myeloid-Derived Suppressor Cells (MDSCs) subpopulations in the spleen and a higher ratio between CD8 and regulatory immune cells in Alpha DaRT-treated tumors. [7] By reducing immune suppression, Alpha DaRT may lift some of the tumor’s natural “brakes” on the immune system, allowing a stronger attack on the cancer.
- Pro-immunogenic Signals Upregulated: Gene expression analysis after Alpha DaRT showed increased activity of pathways like interferon signaling (a hallmark of anti-tumor immunity) and higher expression of cell death, alongside downregulation of DNA repair and cell proliferation signals in the tumor. [7] In simple terms, Alpha DaRT may make the tumor environment hostile to cancer and more visible to the immune system.
These immunogenic effects lay the groundwork for synergy with checkpoint inhibitor immunotherapies. If Alpha DaRT can draw the tumor “battle lines”, it can help rally immune troops to recognize cancer cells. Checkpoint inhibitors, on the other hand, supply those troops with the ammunition to keep fighting by blocking the PD-1/PD-L1 signals that tumors use to disarm T cells. [9]
Synergy with Checkpoint Inhibitors (e.g. Pembrolizumab)
Checkpoint inhibitors like pembrolizumab (Keytruda®) work by releasing the immune system’s brakes, enabling T cells to attack cancer cells more effectively. However, these drugs work best when an army of T cells is already mobilized against the tumor. That’s where Alpha DaRT comes in. Combining Alpha DaRT with a PD-1 checkpoint blocker has shown remarkable synergistic effects in early research. In a preclinical study, tumors treated with the combination of Alpha DaRT + anti-PD-1 had significantly delayed growth compared to either treatment alone. [7] The combo led to greater infiltration of cytotoxic T cells and higher tumor cell killing (marked by granzyme B release) than monotherapy, while also lowering systemic immunosuppressive cells more than either therapy by itself. [7] These findings indicate that Alpha DaRT may create the ideal conditions for checkpoint inhibitors to unleash a more potent and durable immune attack on the cancer.
Importantly, this synergy is not just theoretical – it’s already showing promise in clinical trials. In an ongoing trial for recurrent, inoperable head & neck cancer, the combination of Alpha DaRT with pembrolizumab yielded a 75% objective response rate (ORR) in interim data from Jan-2025 from the first eight patients treated, with 37.5% of patients achieving complete tumor response. These response rates are dramatically higher than historical outcomes with pembrolizumab alone – in a similar patient population, immunotherapy by itself saw approximately 17% ORR and 5% complete responses.[10] While the data are early, they underscore the potential of this combo: patients are responding at a rate 3-4 times better than we would expect with the drug alone. Such results echo what was observed in the lab and strengthen the thesis that Alpha DaRT’s immune-priming effect might translate into real clinical benefit when paired with checkpoint blockade.
A Potential Paradigm Shift in Cancer Care
The potential of Alpha DaRT to marry localized tumor destruction with systemic immune protection could mark a paradigm shift in how we treat solid tumors. Alpha DaRT is poised to enable local therapy to do double duty: not only to kill the targeted tumor, but also to spark an immune response that helps hunt down cancer elsewhere. This is the essence of what is known as “the abscopal effect,” where treating one tumor can lead to regression or growth delay of tumors in other parts of the body via immune mechanisms. [11,12] By reliably inducing this effect, especially when combined with a checkpoint inhibitor, Alpha DaRT could change the treatment paradigm for patients with metastatic or unresectable cancers. It offers the prospect of a one-two punch: direct tumor eradication at the site of disease and a personalized cancer vaccine effect that trains the immune system to seek and destroy cancer cells body-wide – all with minimal side effects / healthy tissue damage and maximal biological efficiency. [1,5,6]
Such an approach is particularly promising for patients who have limited options. For example, in hard-to-treat cancers like recurrent head & neck carcinoma or other solid tumors, a one-time Alpha DaRT procedure followed by immunotherapy might achieve outcomes previously unattainable with immunotherapy alone. Early evidence suggests this strategy can significantly boost the effectiveness of immunotherapy – exactly the kind of innovative leap needed to improve survival in tough cancers.
As research progresses, Alpha DaRT plus checkpoint blockade may emerge as a new front-line or second-line approach in oncology, integrating intratumoral radiotherapeutics and immunotherapy into a cohesive treatment. By harnessing the body’s own immune system to finish the job that local radiation started, this combination exemplifies a more focal, potent, and potentially durable attack on cancer. It’s an exciting development that underscores how multi-modal therapy can reshape cancer care for the better, offering hope for deeper responses and lasting remission even in advanced disease. [7,13]
A Potential Paradigm Shift in Cancer Care
As immunotherapy increasingly moves into the neoadjuvant setting – where treatments are given prior to surgery in order to shrink the tumors before operation, improve resectability, and enhance long-term outcomes – there is a growing opportunity for Alpha DaRT to play a transformative role.
Checkpoint inhibitors such as pembrolizumab are now FDA-approved and are being widely studied in the neoadjuvant setting across a variety of cancers, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric and gastroesophageal junction (GEJ) adenocarcinoma, muscle-invasive bladder cancer, and mismatch repair-deficient rectal cancers. [14,15] These regimens aim to reduce tumor burden before surgery while simultaneously priming systemic immune responses.
Alpha DaRT, with its potential to induce immunogenic cell death and promote antigen release directly within the tumor, may significantly boost this effect. Administering Alpha DaRT in the neoadjuvant setting could further enhance T cell priming, increase pathologic complete response (pCR) rates, reduce the risk of micro-metastatic spread, and improve surgical outcomes. Importantly, using Alpha DaRT while the tumor is still intact offers an optimal window to generate systemic immune activation before the immunosuppressive effects of surgery. Alpha DaRT can even be administered into tumors in traditionally unresectable areas of the body, such as near vital organs, as opposed to conventional radiotherapy. [1,2]
In this context, Alpha DaRT combined with checkpoint inhibitor might serve as a powerful neoadjuvant strategy to augment local control, enable more effective resections, and build lasting immune memory – turning early intervention into long-term protection.
In Summary
With encouraging early trial results, ongoing research, and growing momentum around checkpoint inhibitors in the neoadjuvant setting, Alpha DaRT + immunotherapy is poised to potentially change treatment paradigms – turning once untreatable cancers into ones that can not only be controlled locally, but also attacked everywhere they spread and potentially managed earlier for better long-term outcomes.
References
[1] Popovtzer A, Rosenfeld E, Mizrachi A, et al. Initial safety and tumor control results from a “First-in-Human” multicenter prospective trial evaluating a novel alpha-emitting radionuclide for the treatment of locally advanced recurrent squamous cell carcinomas of the skin and head and neck. Int J Radiat Oncol Biol Phys. 2020;106(3):571-578. doi:10.1016/j.ijrobp.2019.10.048. PMID: 31759075.
[2] Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I. The treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters. Phys Med Biol. 2007;52(16):5025-5042. doi:10.1088/0031-9155/52/16/021. PMID: 17671353.
[3] Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25(1):11-17. doi:10.1016/j.semradonc.2014.07.005. PMID: 25481261.
[4] Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I, Lecanda F. Radiation effects on antitumor immune responses: current perspectives and challenges. Ther Adv Med Oncol. 2018;10:1758834017742575. doi:10.1177/1758834017742575. PMID: 29383033.
[5] Confino H, Hochman I, Efrati M, et al. Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors. Cancer Immunol Immunother. 2015;64(2):191-199. doi:10.1007/s00262-014-1626-8. PMID: 25326364.
[6] Keisari Y, Hochman I, Confino H, Korenstein R, Kelson I. Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments. Cancer Immunol Immunother. 2014;63(1):1-9. doi:10.1007/s00262-013-1462-2. PMID: 23955682.
[7] De Mare S, Nishri Y, Shai A, et al. Diffusing alpha-emitters radiation therapy promotes a proimmunogenic tumor microenvironment and synergizes with programmed cell death protein 1 blockade. Int J Radiat Oncol Biol Phys. 2023;115(3):707-718. doi:10.1016/j.ijrobp.2022.08.043. PMID: 36031029.
[8] Domankevich V, Cohen A, Efrati M, et al. Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response. Cancer Immunol Immunother. 2019;68(12):1949-1958. doi:10.1007/s00262-019-02418-5. PMID: 31667559.
[9] Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi:10.1126/science.aaa8172. PMID: 25838373.
[10] Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7. PMID: 31679945.
[11] Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2015;356(1):82-90. doi:10.1016/j.canlet.2013.09.018. PMID: 24125863.
[12] Bellia SR, Feliciani G, Del Duca M, et al. Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report. J Contemp Brachytherapy. 2019;11(5):449-457. doi:10.5114/jcb.2019.88138. PMID: 31749854.
[13] Keisari Y, Kelson I. The potentiation of anti-tumor immunity by tumor abolition with alpha particles, protons, or carbon ion radiation and its enforcement by combination with immunoadjuvants or inhibitors of immune suppressor cells and checkpoint molecules. Cells. 2021;10(2):228. doi:10.3390/cells10020228. PMID: 33504035.
[14] Wakelee HA, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer (KEYNOTE-671). N Engl J Med. 2024;390(6):491-503. doi:10.1056/NEJMoa2302983. PMID: 38084400.
[15] Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer (KEYNOTE-522). N Engl J Med. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651. PMID: 35139274.
*Note on interim clinical data: The Alpha DaRT + pembrolizumab combination interim data (75% ORR, 37.5% complete response in 8 patients with recurrent/inoperable head & neck cancer) was presented at the Alpha Tau Medical R&D Update Day, January 2025 (NCT05047094). These results have not yet been published in a peer-reviewed journal at the time of writing. Peer-reviewed publication of these clinical trial results is anticipated. For information https://alphatau.com/wp-content/uploads/2026/02/2024-PFIC-Annual-Information-Statement.pdf
